ZERBAXA, (ceftolozane/tazobactam), cephalosporin and β-lactamase inhibitor

No clinical benefit demonstrated in the management of intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections

• ZERBAXA has Marketing Authorisation in the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections.
• Its potential benefit lies in its action against certain resistant gram-negative bacteria, making it possible to treat patients with suspected or documented enterobacter infections due to extended spectrum beta-lactamase (ESBL) producing enterobacteriaceae or to Pseudomonas aeruginosa, within the framework of a carbapenem-sparing regimen.
• The documentation of its clinical efficacy is insufficient in complicated urinary infections (including pyelonephritis) and in complicated intra-abdominal infections, severe intra-abdominal infections and/or intra-abdominal infections due to multiresistant bacteria.
• It can be offered on bacteriological documentation in infections due to susceptible ESBL-producing enterobacteriaceae or Pseudomonas aeruginosa.